Plant-derived, dietary (poly)phenols have potential effects on disease-risk reduction and primary disease prevention. The characterization of (poly)phenol absorption, distribution, metabolism and excretion (ADME) is recognized as crucial step to further advance nutritional and biomedical research of these compounds; and given that (poly)phenols are extensively metabolized after ingestion, accurate assessments of their in vivo metabolites is required. It has become common practice to use unmetabolized parent compounds as reference standards when quantifying (poly)phenol metabolites by LC-MS, although little is known about the accuracy of this approach. To investigate this situation with routinely used LC-MS conditions, the signal yielded by the flavan-3-ol (−)-epicatechin was compared to those of authentic standards of its phase II and microbiota-derived metabolites. The results obtained revealed underestimations up to 94% and overestimations up to 113% of individual epicatechin metabolites. Inaccurate quantitative estimates were also obtained when phase II metabolites of other (poly)phenols were quantified by reference to their unmetabolized parent compounds. This demonstrates the importance of using structurally-identical authentic metabolites as reference compounds when quantifying (poly)phenol metabolites by LC-MS. This is of importance, not just to the accuracy of ADME studies, but for the identification and validation of (poly)phenol metabolites as biomarkers of intake in epidemiological studies.
Introduction
Necessitated by longer life expectancies globally, and by rising health care costs, there is increasing interest in achieving a better understanding of the impact of diet on health and healthy aging [1, 2] . Dietary (poly)phenols are a structurally diverse group of plant-derived bioactives that includes flavonoids, stilbenes, and chlorogenic acids, consumption of which has been linked to potential health benefits in humans [3, 4] . After ingestion, (poly)phenols are extensively modified by a number of reactions, some involving the gut microbiome, resulting in a great diversity of metabolites appearing in the circulatory system as well as being excreted in urine and voided in stools [5, 6] . The identification and quantification of these metabolites, therefore, has a key role in studies on the absorption, distribution, metabolism and excretion (ADME; aka bioavailability) of (poly)phenols [6] [7] [8] [9] . It is now recognized that ADME data are critical in i) the improvement of epidemiological investigations by identifying appropriate metabolites for use as biomarkers of (poly)phenol intake; ii) the planning and interpretation of efficacy and safety studies following (poly)phenols intake; and iii) the design of in vitro and ex vivo investigations aiming to unravel the mechanisms of action underlying the health benefits of (poly)phenols [8, 10, 11] .
In the circumstances, the development and validation of analytical methods for the accurate quantification of (poly)phenol metabolites in human biofluids is an essential part of ADME research and, subsequently, for the extrapolation of ADME data in support of other investigations of (poly)phenols in the wider context of health and nutrition. Current strategies for the quantification of (poly)phenols metabolites are often based on the use of liquid chromatography coupled to mass spectrometry detection (LC-MS) [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . However, the variety of (poly)phenol metabolites generated within the body represent a significant challenge in obtaining authentic analytical reference standards for use in quantification. As a consequence, it has become common practice to use unmetabolized (poly)phenol 'parent compounds' as reference standards for LC-MS-based analytics. One example of this is the use of (−)-epicatechin as a reference standard for the quantification of, (−)-epicatechin-O-glucuronides and methyl-O-(−)-epicatechin-sulfates [12, 14, [19] [20] [21] [22] [23] [24] [25] . Despite the widespread use of this approach, little is known about the potential errors incurred when using unmetabolized (poly)phenols in LC-MS-based quantitative analyses of (poly)phenol metabolites.
Utilizing various LC-MS platforms, in the current study, we investigated the accuracy of quantitative polyphenol metabolite analysis when using unmetabolized (poly)phenols as references standards, and evaluated the impact of this approach on ADME assessments. To accomplish this, we used a variety of (poly)phenols and (poly)phenol metabolites, including structurally-related (−)-epicatechin metabolites (SREMs) and the (−)-epicatechin gut-microbiome-derived 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone metabolites (γVLMs), which were analyzed under 5 chromatographic conditions in 3 different LC-MS systems.
Materials and methods

Chemicals and LC columns
and 3′-O-methyl-(−)-epicatechin-5-sulfate (3′ME5S), synthesized and characterized as described elsewhere [26] [27] [28] [29] , were supplied by the Institute of Pharmaceutical Discovery, LLC (Branford, CT). 5 (3′,4′Di-hydroxyphenyl)-γ-valerolactone (γVL), 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-O-glucuronide (γVL3′G) and 5-(4′-hydroxyphenyl)-γ-valerolactone-3′-sulfate (γVL3′S) were also obtained from the Institute of Pharmaceutical Discovery, LLC. Hesperetin-3′-O-glucuronide, genistein, genistein-7-O-glucuronide, genistein-7-sulfate, resveratrol, resveratrol-3-O-glucuronide were purchased from Toronto Research Chemicals, (Toronto, Canada). (−)-Epicatechin, apigenin, hesperetin, quercetin and quercetin-3-O-glucuronide were obtained from Sigma-Aldrich (St Louis, MO). Apigenin-7-O-glucuronide was supplied by HWI Analytik GMBH (Rülzheim, Germany). The structures of (poly)phenols and their metabolites used in the study are illustrated in Fig. 1 . HPLC columns were obtained from Phenomenex (Torrance, CA). HPLC grade methanol, acetonitrile and water were purchased from Fischer Chemical (Fair Lawn, NJ).
LC-MS instrumentation
Samples were analyzed in triplicate using three LC-MS systems, operated using electrospray ionisation in negative ion mode, and optimized for (−)-epicatechin and γVL detection. In all instances, samples were dissolved in the mobile phase used at the start of LC mobile phase gradient. Compounds were analyzed at the following concentrations: 0.25, 1, 5 and 10 µM. An autosampler was used at 4°C. The injection volume was 25 µL and chromatography was carried out at 25°C using LC columns and mobile phase conditions 1-5 listed in Table 1 .
The three LC-MS systems use were: 
Quantification of metabolites
The slope of the response curve for each compound was calculated employing the respective instrument operating software, and using least-square linear regression with the intercept set as 0 and 1/x2 weighing. When phase II metabolite standards are not available, metabolites are quantified using the response curve of the unmetabolized parent compound. Results were also calculated as the change of the slope of the metabolite response curve relative to the slope of the unmetabolized parent compound response curve, i.e. SREMs vs. (−)-epicatechin and γ-VLMs vs. γ-VL, and expressed in percentage, whereas i) values equal to 0% indicated that both metabolite and unmetabolized compound yield a similar signal and, thus, are interchangeable as reference standards; ii) values higher than 0% indicated that the metabolite yielded a signal greater to that of the unmetabolized compound, which would result in overestimations of concentrations of the metabolite when using the parent compound as standard; and iii) values lower than 0% indicated that the metabolite yielded a signal lower to that of the unmetabolized compound, which would result in underestimations of concentrations of the metabolite when using the unmetabolized (poly)phenol as standard.
True concentrations of (−)-epicatechin metabolites were determined in plasma collected after the intake of [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C](−)-epicatechin which was analyzed via LC-MS using authentic metabolite standards [8] . The estimated concentration of (−)-epicatechin metabolites in these plasma samples obtained using LC-MS systems A, B and C and LC method 5, were calculated by correcting the true plasma concentrations by the relative response between the individual (−)-epicatechin metabolite and its corresponding unmetabolized form (either (−)-epicatechin or γVL). From the data obtained, different ADME parameters, including peak plasma concentration (C max ), time to reach C max (T max ), plasma area under the curve (AUC) and elimination half-life (t 1/2 ) of SREMs and γVLMs were calculated.
Results
Errors in the estimation of (−)-epicatechin metabolite concentrations when using unmetabolized (−)-epicatechin and γVL as reference standards
Standard curves for (−)-epicatechin, the SREMs, E3′G, E3′S, 3′ME5G and 3′ME5S, γVL and the γVLM, γVL3′G and γVL3′S were prepared using LC methods 1-5 (Table 1) in LC-MS system A. The signal of SREMs and γVLMs were expressed relative to the signal of (−)-epicatechin and γVL, respectively and expressed as a percentage. Positive and negative deviations from 0% represented over-and under-estimations when assessing (−)-epicatechin metabolites concentrations using unmetabolized (−)-epicatechin as the reference standard, respectively ( Table 2 ). The signal of SREMs differed to that of (−)-epicatechin, with responses ranging from − 88% to + 113% of the signal yielded by (−)-epicatechin. With the exception of LC method 4, the response of the glucuronide, E3′G, resulted in inaccurate overestimates, while, with the exception of E3′S in method 1, the response of the other SREMs was less than that of (−)-epicatechin. Similar results were obtained when γVLMs were analyzed relative to γVL. The response of the γVL-3′-Osulfate was − 94% to − 79% of that of γVL while the glucurondie was overestimated with the exception of method 3 ( Table 2 ). It is of note that when (−)-epicatechin is used as reference compound for the quantitative analysis of γVL and γVLMs results of even greater inaccuracy are obtained (Supplementary Table 6 ).
The comparative performance of LC method 5 on LC-MS systems A, B, and C was evaluated to assess the influence of different MS platforms on analytical outcomes. The data obtained clearly demonstrate that there were substantial differences in the response to each SREM depending on the instrumentation used (Table 2 ). For instance, 3′ME5G was underestimated using LC-MS system A and B, but overestimated with instrument C. The response of γVL3'G was − 84% of that of (−)-epicatechin using LC-MS system A, while with LC-MS systems B and C, respectively, it was + 205% and + 250%, of that of (−)-epicatechin.
Errors in determining plasma pharmacokinetics of SREMs and γVLMs when using (−)-epicatechin and γVL as reference standards
The impact of using (−)-epicatechin and γVL as reference standards when assessing plasma pharmacokinetic parameters of SREMs and γVLMs was investigated. To this end, SREM and γVLM concentrations in human plasma collected after feeding [2- 14 C](−)-epicatechin and determined with authentic reference compounds [8] were compared with data obtained when samples were analyzed with LC method 5 using LC-MS systems A, B and C with (−)-epicatechin and γVL as reference compounds. This revealed significant over-and underestimations of the C max of both SREMs and γVLMs, which were dependent on the LC-MS (Fig. 2) . For example, LC-MS system A yielded a lower concentration of 3′ME5S than those determined using authentic reference compounds, while LC-MS system B resulted in overestimates of 3′ME5S levels. Similar inaccuracies were observed with area-under-thecurve (AUC) estimates ( Supplementary Fig. 1 ). Another important parameter affected by the use of (−)-epicatechin and γVL as the reference standards was the profile of metabolites. Based on AUC data, the relative abundance of each SREM and γVLM in plasma was calculated (Fig. 3) . The major SREM in humans, E3′G, represented 22 ± 9% of (−)-epicatechin metabolites when determined using authentic metabolites, but accounted for only 9 ± 5% when quantified by reference to (−)-epicatechin using LC-MS system B (Fig. 3) . In addition, the relative abundance of γVL3'S accounted for 43% of (−)-epicatechin metabolites, but when quantified in γVL equivalents, γVL3'S abundance fluctuated between 10 ± 4% when using LC-MS system A to 69 ± 9% when using LC-MS system C.
Errors in the assessment of other (poly)phenol metabolite concentrations when using the unmetabolized (poly)phenols as reference compounds
To determine if the findings obtained with SREMs and γVLMs can be Table 2 LC-MS analysis of 0.25-10 µM (-)-epicatechin and SREMs by reference to (-)-epicatechin, and γVLMs by reference to γVL, using LC conditions 1-5 and LC-MS system A, B and C. (see Table 1 ). Data are mean values (n = 3), expressed as a % of the slope of the response of the reference compound, with SE < 10% of mean values. 
a SREMs, structurally-related ( Table 1 ). Data are mean values (n = 3) with SD < 10% of mean values and expressed as % of the slope of the corresponding aglycone. extrapolated to other (poly)phenol metabolites, a number of (poly) phenols and their phase II metabolites were analyzed using LC method 5 with LC-MS system A. The data obtained are summarized in Fig. 4 . Consistent with the findings for (−)-epicatechin in the previous section, it is evident that the signals of the phase II metabolites were substantially different from those of the corresponding unmetabolized (poly)phenol. In particular, the signal of apigenin-7-O-glucuronide was 25 times higher than that of apigenin. In contrast, the response of the aglycone hesperetin was 50 times greater than that of hesperetin-3′-Oglucuronide. The response of genistein-based isoflavones was very different with a marked 1088% over-estimate for genistein-7-O-glucuronide. Similar differences were observed in the signal between (poly) phenol and (poly)phenol metabolites when analyzed using a different LC-MS system (Supplementary Table 7 ).
Errors in the assessment of (poly)phenol metabolite concentrations by reference to other (poly)phenol metabolites
Due to the complexity of (poly)phenol metabolism, it is challenging to acquire standards for all potential phase II metabolites. We, therefore, evaluated the responses to different (poly)phenol metabolites, rather than the unmetabolized parent aglycone, to ascertain if one (poly)phenol metabolite could be used as a reference standard for another (poly)phenol metabolite. To accomplish this, a number of (−)-epicatechin metabolites, including 16 different SREMs and 8 different γVLMs were analyzed using method LC method 5 and LC-MS system A. The signal strength of each metabolite was compared to those of the other (−)-epicatechin metabolites. The results obtained show that metabolites with the same conjugation type, but different site of conjugation (i.e. positional isomeric metabolites) present similar responses within that group, but large differences became apparent when comparing the signal strength with that of other metabolites (Fig. 5) . For instance, (−)-epicatechin sulfates, including E3′S, E4′S, E5S and E5S, showed signals that averaged 102 ± 20% within this group, while large differences, higher than 50% or lower than 50%, were observed when compared to other types of SREMs (i.e. 316 ± 141% vs.
(−)-epicatechin glucuronides).
Discussion
We investigated whether or not the use of unmetabolized 'parent compounds' or 'related metabolites' in lieu of structurally-identical authentic metabolites as analytical reference standards in the quantitative analysis of (poly)phenol metabolites is yielding sufficiently accurate results. The data obtained shows that the LC-MS quantification of SREMs and γVLMs by reference to their respective unmetabolized parent compound produces inaccurate over-and under-estimates (Table 2) , which is also influenced to varying degrees by the chromatographic conditions and MS instruments that are used. In addition, the data demonstrate that the use of unmetabolized (−)-epicatechin and γVL to determine the concentrations of SREMs and γVLMs, respectively, results in substantial errors when estimating ADME parameters (Figs. 2  and 3 ). Furthermore, it was also demonstrated that the problems of inaccurate quantitative analyses are not confined to flavan-3-ol-derived metabolites but also apply, in some instances to an even greater extent, to LC-MS-based assessments of other (poly)phenol phase II metabolites (Fig. 4) . Given that different researchers use different HPLC methods and columns and MS instruments to quantify (poly)phenol metabolites, the findings indicate that there exist substantial inter-laboratory variations in the levels of (poly)phenol metabolites reported in literature, limiting the value of detailed comparisons of the data obtained in these studies.
Initially, analytical methods for the quantification of (poly)phenol metabolites were based on the use of glucuronidase/sulfate enzymes, which release aglycones, such as hesperetin, quercetin, and (−)-epicatechin, from their conjugated metabolites. With this technique, samples were then quantified by LC using readily available aglycones as reference standards [30] [31] [32] [33] [34] [35] [36] [37] . However, enzymatic hydrolysis-based methodologies have been proven to yield inaccurate estimates of (poly) phenol metabolite concentrations, because of substantial batch-to-batch variations in the enzymes and the restricted efficacy of the enzyme preparations to completely hydrolyze metabolites [18, [38] [39] [40] . LC-MS methods represented a significant improvement for the quantification of (poly)phenol metabolites as these methods permitted the identification of individual metabolites. However, the data presented in this paper demonstrate that LC-MS methods also result in inaccurate quantitatve assessments of (poly)phenol metabolites when relying solely on the use of unmetabolized (poly)phenols as reference standards. It is, therefore, evident that further advancements of LC-MS methodology in the area of (poly)phenol metabolite analysis will require the use of authentic metabolites as reference standards. This will not only permit generating standard curves for accurate quantifications, but it will also enable analytical methods, including sample preparation, to be fully validated [38, 39, [41] [42] [43] . Nevertheless, we do recognize that it would be unrealistic to assume that all required metabolite standards should be available at the initial stages of the investigation of the ADME of a given dietary (poly)phenol. In such instances, we consider that it would perhaps be adequate to use surrogate-reference standards like unmetabolized polyphenols or, even better, positional isomeric metabolites (Fig. 5) to gain insights into the type of metabolites and their approximate concentrations. However, subsequent work, aimed at validating initial insights and at providing acceptably accurate analytical data, would need to be conducted with authentic standards.
In recent years, a variety of methods have been published for the synthesis of (−)-epicatechin metabolites [26] [27] [28] [29] [43] [44] [45] [46] [47] . The availability of authentic standards of (−)-epicatechin metabolites permitted accurate estimations of the ADME of (−)-epicatechin to be obtained [38, 39] that were subsequently corroborated and further expanded with the use of radiolabeled (−)-epicatechin studies in humans [8] and rodents [48] . As a consequence of this, data on the ADME of (−)-epicatechin are now being used for: i) the interpretation of dietary intervention studies, including in the interaction with other dietary compounds such as methylxanthines [49] ; ii) the design of mechanism of action studies by understanding the concentration, chemical identity and tissue distribution of SREMs and γVLMs [50, 51] ; iii) identification of candidate biomarkers of (−)-epicatechin intake based on the specificity, abundance and plasma half-life of γVLMs [11] ; and iv) the design of appropriate studies to characterize the safety profile of flavan-3-ols given the limitations of using animal models due to species-dependent differences in ADME of these compounds [8, 48, 52] . There are other (poly)phenols in the diet that still require accurate ADME characterization to further advance on their nutritional and biomedical relevance, and for which the availability of authentic (poly)phenol metabolites will be a pre-requisite. However, it is encouraging that synthesis procedures are available for many (poly)phenol-derived metabolites [44, 53] and, for convenience, an increasing number can now be obtained from commercial sources at affordable prices.
Conclusions
It is evident that ultimately, the accurate quantitative analysis of (poly)phenols metabolites requires the use of authentic reference compounds. The importance of accurate data on the ADME of (poly) phenols in the context of research in this area can hardly be overestimated, as it is foundational to the meaningful interpretation of epidemiological studies, clinical dietary interventions, and work in cell culture systems aimed at elucidating molecular mechanisms of actions. In this context, all efforts should be made to enable the wider use of authentic standards through: (a) developing novel chemical synthesis strategies, (b) utilizing published synthesis procedures, and (c) making use of the increasing availability of authentic standards from commercial sources. Finally, the development of validated analytical methods for the accurate quantitative and qualitative assessment of (poly)phenol metabolites in biological samples is an essential prerequisite for advancing our general understanding of this particular group of bioactives, and the roles they may play in nutrition and primary disease prevention.
